Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 332 participants.

Also called NCT04349683

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 332 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04349683
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04349683. Randomized; double masking; primary purpose treatment. Start 2020-04-30 (anticipated); primary completion 2021-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis
Condition
Chronic Kidney Disease Stage 3B
Condition
Chronic Kidney Disease stage4
Condition
Glomerulonephritis
Intervention (Drug)
Jinshuibao
Intervention (Drug)
Placebo
Lead sponsor
Jemincare (class: industry)
Collaborator
Shanghai 6th People's Hospital (class: other)

Record details

Record id
cardio:ct-nct04349683
Content hash
692cb205975575be20d946b5ec618b679645928639b6b64202dfb42d55aabe5e